Regor Therapeutics Group

News

Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors to Roche's Genentech for an upfront cash payment of $850 million.

News

A $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.